Why Cepheid Shares Dropped

Before you go, we thought you'd like these...
Before you go close icon

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of molecular diagnostics company Cepheid (NAS: CPHD) dipped as much as 10% earlier in the trading session, after updating guidance for the upcoming quarter.

So what: Cepheid warned after the bell last night that, due to parts problems with its Xpert family of diagnostic tests, about $5 million in product that would have shipped in the third-quarter will be pushed back into the fourth-quarter. As such, Cepheid now expects to report revenue in the range of $79 million to $81 million, versus Wall Street's projections for $84 million in sales. Cepheid was able to keep its full-year sales forecast intact.


Now what: Capacity is always a concern, and it looks like Cepheid got caught with its hand in the cookie jar while attempting to upgrade to higher production capacity. The prospect for the diagnostics market is bright, as new technologies in the health-care sector are making it cheaper and more feasible than ever to utilize Cepheid's products; but, at 95 times forward earnings, and almost 11 times book value, I'm not as excited about Cepheid. Until it can put some meat on its bones (i.e. earn a sizable profit), I'm just not going to be a fan.

Craving more input? Start by adding Cepheid to your free and personalized Watchlist so you can keep up on the latest news with the company.

The article Why Cepheid Shares Dropped originally appeared on Fool.com.

Fool contributorSean Williamshas no material interest in any companies mentioned in this article. You can follow him on CAPS under the screen nameTMFUltraLong, track every pick he makes under the screen nameTrackUltraLong, and check him out on Twitter, where he goes by the handle@TMFUltraLong.Try any of our Foolish newsletter servicesfree for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has adisclosure policy.

Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story

Want more news like this?

Sign up for Finance Report by AOL and get everything from business news to personal finance tips delivered directly to your inbox daily!

Subscribe to our other newsletters

Emails may offer personalized content or ads. Learn more. You may unsubscribe any time.

From Our Partners